Resolution of the Expert Council: “Evidence base and the role of low-dose multicomponent pharmacotherapy”
D.A. Sychev, A.M. Lila, S.A. Bozhkova, L.N. Gavrilenko, S.K. Zyryanov, A.V. Naumov, M.G. Poluektov, I.V. Sorokovikov, E.A. Taskina, R.A. Teryan, N.E. Usacheva
Expert Council participants:
Dmitry A. Sychev, MD, Dr. Sci. (Medicine), professor, academician of RAS, Honored Scientist of the Russian Federation, director of the World-Class Genomic Research Center “Center for Predictive Genetics, Pharmacogenetics, and Personalized Therapy”, Academician B.V. Petrovsky National Research Center of Surgery; head of the Department of clinical pharmacology and therapy named after academician B.E. Votchal, Russian Medical Academy of Continuous Professional Education; president of the Eurasian Association of Clinical Pharmacology and Pharmacovigilance (Moscow, Russian Federation)
Aleksander M. Lila, MD, Dr. Sci. (Medicine), professor, corresponding member of RAS, Honored Physician of the Russian Federation, director of V.A. Nasonova Research Institute of Rheumatology; head of the Department of rheumatology, Russian Medical Academy of Continuous Professional Education; chief external expert in rheumatology of the Ministry of Healthcare of Russia (Moscow, Russian Federation)
Svetlana A. Bozhkova, MD, Dr. Sci. (Medicine), professor, head of the Scientific Department for the prevention and treatment of wound infections and the Department of clinical pharmacology, R.R. Vreden National Medical Research Center for Traumatology and Orthopedics (Saint Petersburg, Russian Federation)
Larisa N. Gavrilenko, MD, PhD (Medicine), associate professor, professor of the Department of clinical pharmacology, Belarusian State Medical University; chairman of the board of the Public Medical Association “Clinical pharmacology and therapy” (Minsk, Republic of Belarus)
Sergey K. Zyryanov, MD, Dr. Sci. (Medicine), professor, chief specialist in clinical research for the Department of Healthcare of Moscow; head of the Department of general and clinical pharmacology, RUDN University (Moscow, Russian Federation)
Anton V. Naumov, MD, Dr. Sci. (Medicine), professor of the Department of age-related diseases and head of the Department for musculoskeletal disorders of Russian Gerontological Research and Clinical Center, N.I. Pirogov Russian National Research Medical University (Moscow, Russian Federation)
Mikhail G. Poluektov, MD, PhD (Medicine), associate professor of the Department of nervous diseases and neurosurgery of the Institute of clinical medicine and head of the Sleep Medicine Unit of the University Clinical Hospital No. 3, I.M. Sechenov First Moscow State Medical University (Sechenov University) (Moscow, Russian Federation)
Ivan V. Sorokovikov, MD, head of the Department of development and external communications, Center for Medical Care Expertise and Quality Control (Moscow, Russian Federation)
Elena A. Taskina, MD, PhD (Medicine), senior researcher at the Department of metabolic bone and joint diseases, V.A. Nasonova Research Institute of Rheumatology (Moscow, Russian Federation)
Rozi A. Teryan, MD, PhD (Medicine), head of the Department for the methodology of development and expert evaluation of clinical guidelines, Center for Expertise and Quality Control of Medical Care; assistant at the Department of healthcare organization and public health (with a course on healthcare technologies assessment), Russian Medical Academy of Continuous Professional Education (Moscow, Russian Federation)
Natalya E. Usacheva, MD, PhD (Pharmacology), deputy head of the Department for the methodology of development and expert evaluation of clinical guidelines, Center for Medical Care Expertise and Quality Control (Moscow, Russian Federation)
Abstract. Current article presents the key points and conclusions from an expert Council meeting held in September 2026, which focused on analyzing current data regarding the use of low-dose multicomponent preparations for osteoarthritis (OA) and associated conditions. Participants reviewed the results of preclinical and clinical studies on Traumeel® S, Zeel® T, and Neurexan® preparations, and discussed their mechanisms of action, efficacy, safety, and role in contemporary clinical practice. Particular attention was given to issues of comorbidity, polypharmacy, and the limitations of standard OA therapy. The information presented confirms that these low-dose multicomponent preparations are supported by a robust evidence base, which includes experimental studies, randomized controlled trials, and real-world clinical practice data. Following the discussion, the potential for using these medicinal products as part of a comprehensive treatment approach for patients with osteoarthritis (OA), anxiety disorders, and sleep disturbances was highlighted.
The resolution of the Expert Council, titled “Evidence base and the role of low-dose multicomponent pharmacotherapy,” was approved by the Expert Council participants on September 16, 2026.
Keywords
References
- Martel-Pelletier J, Barr AJ, Cicuttini FM, Conaghan PG, Cooper C, Goldring MB, et al. Osteoarthritis. Nat Rev Dis Primers. 2016;2:16072.
PMID: 27734845. https://doi.org/10.1038/nrdp.2016.72
- Johnson V, Hunter D. The epidemiology of osteoarthritis. Best Pract Res Clin Rheumatol. 2014;28(1):5–15.
PMID: 24792942. https://doi.org/10.1016/j.berh.2014.01.004
- Laine L, Smith R, Min K, Chen C, Dubois RW. Systematic review: The lower gastrointestinal adverse effects of non-steroidal antiinflammatory drugs. Aliment Pharmacol Ther. 2006;24(5):751–67.
PMID: 16918879. https://doi.org/10.1111/j.1365-2036.2006.03043.x
- Rostom A, Muir K, Dube C, Jolicoeur E, Boucher M, Joyce J, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: A Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol. 2007;5(7):818–28, 828.e1–5; quiz 768.
PMID: 17556027. https://doi.org/10.1016/j.cgh.2007.03.011
- Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578–89.
PMID: 31278997. https://doi.org/10.1016/j.joca.2019.06.011
- Coxib and traditional NSAID Trialists’ (CNT) Collaboration; Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: Meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769.
PMID: 23726390. PMCID: PMC3778977. https://doi.org/10.1016/S0140-6736(13)60900-9
- Fukuda K, Miyamae F, Tomita K, Yamaashi T, Ogawa Y, Yatsumoto K, et al. Association between chronic kidney disease and synergistic, potentially nephrotoxic medication use in elderly hospitalized patients. Int J Clin Pharmacol Ther. 2019;57(7):353–61.
PMID: 31094316. https://doi.org/10.5414/CP203429
- Schjerning Olsen AM, Gislason GH, McGettigan P, Fosbol E, Sorensen R, Hansen ML, et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA. 2015;313(8):805–14.
PMID: 25710657. https://doi.org/10.1001/jama.2015.0809
- Lo-Ciganic WH, Floden L, Lee JK, Ashbeck EL, Zhou L, Chinthammit C, et al. Analgesic use and risk of recurrent falls in participants with or at risk of knee osteoarthritis: Data from the Osteoarthritis Initiative. Osteoarthritis Cartilage. 2017;25(9):1390–98.
PMID: 28385483. PMCID: PMC5989560. https://doi.org/10.1016/j.joca.2017.03.017
- Leong R, Chan F. Drug-induced side effects affecting the gastrointestinal tract. Expert Opin Drug Saf. 2006;5(4):585–92.
PMID: 16774495. https://doi.org/10.1517/14740338.5.4.585
- Arroll B, Goodyear-Smith F. Corticosteroid injections for osteoarthritis of the knee: Meta-analysis. BMJ. 2004;328(7444):869.
PMID: 15039276. PMCID: PMC387479. https://doi.org/10.1136/bmj.38039.573970.7C
- Коршунов Н.И., Речкина Е.В., Филатова Ю.С., Яльцева Н.В. Остеоартрит и депрессия. Научно-практическая ревматология. 2018;56(1):93–98. [Korshunov NI, Rechkina EV, Filatova YuS, Yaltseva NV. Osteoarthritis and depression. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2018;56(1):93–98 (In Russ.)].
EDN: OTKLTB. https://doi.org/10.14412/1995-4484-2018-93-98
- Rodriguez Marquez MA, Espinosa Morales R. Comparison of the use of potentially inappropriate medications and drug-drug interactions in patients aged over 65 with diagnoses of osteoarthritis and rheumatoid arthritis. Invest Discapacidad. 2025;11(S1).
- Официальный интернет-портал правовой информации (pravo.gov.ru). Приказ Министерства здравоохранения Российской Федерации от 28.02.2019 № 103н «Об утверждении порядка и сроков разработки клинических рекомендаций, их пересмотра, типовой формы клинических рекомендаций и требований к их структуре, составу и научной обоснованности включаемой в клинические рекомендации информации» (зарегистрирован 08.05.2019 № 54588). Доступ: http://publication.pravo.gov.ru/Document/View/0001201905080038 (дата обращения – 17.09.2026). [Official Internet Portal of Legal Information (pravo.gov.ru). Order of the Ministry of Healthcare of Russia dated February 28, 2019, No. 103n “On approval of the procedure and timelines for the development and revision of clinical guidelines, the standard template for clinical guidelines, and requirements for their structure, content, and the scientific validity of information included therein” (registered on May 8, 2019, No. 54588). URL: http://publication.pravo.gov.ru/Document/View/0001201905080038 (date of access – 17.09.2026) (In Russ.)].
- Duller S, Bader M, Uhl O, Wergin M. Chemical characterization of Nuxean: Composition of a multicomponent natural veterinary medicinal product. Front Vet Sci. 2026;13:1769201.
PMID: 41800299. PMCID: PMC12962933. https://doi.org/10.3389/fvets.2026.1769201
- Dunkel A, Duller S, Alban S, Strupp M, Lehner L. Liquid chromatography-mass spectrometry-based molecular profiling of Vertigoheel®. Int J Mol Sci. 2026;27(4):1893.
PMID: 41752030. PMCID: PMC12941094. https://doi.org/10.3390/ijms27041893
- ЛС ГЭОТАР. ОХЛП Цель® Т раствор для внутримышечного введения. Регистрационный номер ЛП-№(000286)-(РГ-RU) от 21.06.2021. Доступ: https://www.lsgeotar.ru/drugs/zeel-t-AGR_ (дата обращения – 17.09.2026). [LS GEOTAR. General characteristics of the medicinal product Zeel® T, solution for intramuscular injection. Registration number ЛП-№(000286)-(РГ-RU) dated 21.06.2021. URL: https://www.lsgeotar.ru/drugs/zeel-t-AGR_ (date of access – 17.09.2026) (In Russ.)].
- ЛС ГЭОТАР. ОХЛП Траумель® С раствор для внутримышечного и околосуставного введения. Регистрационный номер ЛП-№(000269)-(РГ-RU) от 08.06.2021. Доступ: https://www.lsgeotar.ru/drugs/traumeel-s-AGLf (дата обращения – 17.09.2026). [LS GEOTAR. General characteristics of the medicinal product Traumeel® S, solution for intramuscular and periarticular injection. Registration number ЛП-№(000269)-(RG-RU) dated 08.06.2021. URL: https://www.lsgeotar.ru/drugs/traumeel-s-AGLf (date of access – 17.09.2026) (In Russ.)].
- Herman PM, Crawford CC, Maglione MA, Newberry SJ, Amieux PS, Blyden-Taylor K, et al. The current state of the quality of homeopathic clinical research. Complement Ther Med. 2025;88:103108.
PMID: 39551363. PMCID: PMC12158618. https://doi.org/10.1016/j.ctim.2024.103108
- Зырянов С.К., Строк А.Б. Низкопотенцированные гомеопатические препараты: исторический обзор и сравнительный анализ с аллопатическим и фитотерапевтическим подходами. Фармация и фармакология. 2026;14(3):236–47. [Zyryanov SK, Strok AB. Low-potential homeopathic medicines: Historical review and comparative analysis with allopathic and phytotherapeutic approaches. Farmatsiya i farmakologiya = Pharmacy and Pharmacology. 2026;14(3):236–47 (In Russ.)].
EDN: HCDIGR. https://doi.org/10.19163/2307-9266-2026-14-3-236-247
- St Laurent G 3rd, Toma I, Seilheimer B, Cesnulevicius K, Schultz M, Tackett M, et al. RNAseq analysis of treatment-dependent signaling changes during inflammation in a mouse cutaneous wound healing model. BMC Genomics. 2021;22(1):854.
PMID: 34823472. PMCID: PMC8614049. https://doi.org/10.1186/s12864-021-08083-2
- Hoch M, Smita S, Cesnulevicius K, Schultz M, Lescheid D, Wolkenhauer O, Gupta S. Network analyses reveal new insights into the effect of multicomponent Tr14 compared to single-component diclofenac in an acute inflammation model. J Inflamm (Lond). 2023;20(1):1.
PMID: 36973809. PMCID: PMC10044762. https://doi.org/10.1186/s12950-023-00335-0
- Jordan PM, van Goethem E, Muller AM, Hemmer K, Gavioli V, Baillif V, et al. The natural combination medicine Traumeel (Tr14) improves resolution of inflammation by promoting the biosynthesis of specialized pro-resolving mediators. Pharmaceuticals (Basel). 2021;14(11):1123.
PMID: 34832905. PMCID: PMC8623904. https://doi.org/10.3390/ph1411112
- Porozov S, Cahalon L, Weiser M, Branski D, Lider O, Oberbaum M. Inhibition of IL-1beta and TNF-alpha secretion from resting and activated human immunocytes by the homeopathic medication Traumeel S. Clin Dev Immunol. 2004;11(2):143–49.
PMID: 15330450. PMCID: PMC2270708. https://doi.org/10.1080/10446670410001722203
- Казимирский А.Н., Салмаси Ж.М., Порядин Г.В., Кукес И.В. Результаты комплексного иммуннофармакологического изучения механизмов действия биорегуляционных препаратов. Бюллетень экспериментальной биологии и медицины. 2021;172(7):48–51. [Kazimirskii AN, Salmasi ZhM, Poryadin GV, Kukes IV. Results of complex immunopharmacological analysis of the mechanisms of action of bioregulation agents. Byulleten' eksperimental’noy biologii i meditsiny = Bulletin of Experimental Biology and Medicine. 2021;172(7):48–51 (In Russ.)].
EDN: VZCXDR. https://doi.org/10.47056/0365-9615-2021-172-7-48-51
- St Laurent G 3rd, Seilheimer B, Tackett M, Zhou J, Shtokalo D, Vyatkin Y, et al. Deep sequencing transcriptome analysis of murine wound healing: Effects of a multicomponent, multitarget natural product therapy-Tr14. Front Mol Biosci. 2017;4:57.
PMID: 28879183. PMCID: PMC5572416. https://doi.org/10.3389/fmolb.2017.00057
- Sanchez C, Hemmer K, Krommelbein N, Seilheimer B, Dubuc JE, Antoine C, Henrotin Y. Reduction of matrix metallopeptidase13 and promotion of chondrogenesis by Zeel T in primary human osteoarthritic chondrocytes. Front Pharmacol. 2021;12:635034.
PMID: 34045958. PMCID: PMC8144641. https://doi.org/10.3389/fphar.2021.635034
- Jaggi R, Wurgler U, Grandjean F, Weiser M. Dual inhibition of 5-lipoxygenase/cyclooxygenase by a reconstituted homeopathic remedy; Possible explanation for clinical efficacy and favourable gastrointestinal tolerability. Inflamm Res. 2004;53(4):150–57.
PMID: 15060721. https://doi.org/10.1007/s00011-003-1236-y
- Schmolz M, Heine H. [Homeopathic substances from antihomotoxic medicine modulate the synthesis of TGF-β1 in human whole-blood cultures]. Biol Med. 2001;30(2):61–65 (In German).
- Поздняков Д.И., Кукес И.В. Доклиническое исследование влияния препарата Цель® Т на воспалительные и регенераторные процессы при остеоартрите. Лекарственные средства и рациональная фармакотерапия. 2026;2(19):10–20. [Pozdnyakov DI, Kukes IV. Preclinical study of the effect of the drug Zееl T on inflammatory and regenerative processes in osteoarthritis. Lekarstvennyye sredstva i ratsional’naya farmakoterapiya = Drugs and Rational Pharmacotherapy. 2026;2(19):10–20 (In Russ.)].
https://doi.org/10.56356/27827259_2026_19_10
- Stancikova M, Bely M, Svik K, et al. Effects of Zeel comp. on experimental osteoarthritis in rabbit knee. Rheumatologia. 1999;13(3):101–8.
- Birnesser H, Klein HP, Weiser M. A modern homeopathic medication works as well as COX2 inhibitors. Der Allgemeinarzt. 2003;25:261–64.
- Gottwald R, Weiser M. Treatment of osteoarthritis of the knee with Zeel T. Medicina Biologica. 2000;13(4):109–13.
- Wodick RE, Steininger K, Zenner S. Treatment of degenerative articular affections with Zeel ointment: Results of a prospective drug survey conducted with 498 patients. Biologische Medizin. 1993;3:127–35.
- Nahler G, Metelmann H, Sperber H. [Treatment of knee osteoarthritis with Zeel comp. – Results of a randomized, controlled clinical trial in comparison with hyaluronic acid]. Orthopadische Praxis. 1996;32(5):354–59 (In German).
- Maronna U, Weiser M, Klein P. [Oral treatment of knee osteoarthritis with Zeel comp. – Results of a double-blind equivalence study versus diclofenac]. Orthopadische Praxis. 2000;36(5):285–91 (In German).
- Lozada C, del Rio E, Reitberg D, Smith R, Kahn C, Moskowitz RW. A multi-center double-blind, randomized, controlled trial (db-RCT) to evaluate the effectiveness and safety of co-administered Traumeel® (Tr14) and Zeel® (Ze14) intra-articular (IA) injections versus IA placebo in patients with moderate-to-severe pain associated with OA of the knee. Arthritis Rheumatol. 2014;66(Suppl):S1266. Abstract 2896.
- Алексеева Л.И., Мазуров В.И., Зонова Е.В., Ершова О.Б., Решетько О.В. Результаты клинического исследования препаратов Траумель® С и Цель® Т у пациентов с остеоартритом коленного сустава, имеющих сопутствующие сердечно-сосудистые заболевания. Современная ревматология. 2023;17(5):79–86. [Alekseeva LI, Mazurov VI, Zonova EV, Ershova OB, Reshetko OV. Results of a clinical study of Traumeel® S and Zeel® T in patients with knee osteoarthritis and concomitant cardiovascular disease. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2023;17(5):79–86 (In Russ.)].
EDN: FPXOWA. https://doi.org/10.14412/1996-7012-2023-5-79-86
- Doering BK, Wegner A, Hadamitzky M, Engler H, Rief W, Schedlowski M. Effects of Neurexan® in an experimental acute stress setting – an explorative double-blind study in healthy volunteers. Life Sci. 2016;146:139–47.
PMID: 26772822. https://doi.org/10.1016/j.lfs.2015.12.058
- Dimpfel W. Effects of Neurexan® on stress-induced changes of spectral EEG power: A double-blind, randomized, placebo-controlled, crossover exploratory trial in human volunteers. World J Neurosci. 2019;9(3):100–12.
https://doi.org/10.4236/wjns.2019.93007
- Mayer K, Krylova M, Alizadeh S, Jamalabadi H, van der Meer J, Vester JC, et al. Nx4 reduced susceptibility to distraction in an attention modulation task. Front Psychiatry. 2021;12:746215.
PMID: 34912250. PMCID: PMC8667722. https://doi.org/10.3389/fpsyt.2021.746215
- Chand T, Alizadeh S, Li M, Fan Y, Jamalabadi H, Danyeli L, et al. Nx4 modulated resting state functional connectivity between amygdala and prefrontal cortex in a placebo-controlled, crossover trial. Brain Connect. 2022;12(9):812–22.
PMID: 35438535. PMCID: PMC9805862. https://doi.org/10.1089/brain.2021.0189
- Hajak G, Vetter C, Wehling M. Neurexan prescription is associated with lower risk of sleep disorder recurrence and depression prevalence as compared to Z-drugs and benzodiazepines: A retrospective database analysis in Germany. Healthcare (Basel). 2024;12(14):1413.
PMID: 39057556. PMCID: PMC11276089. https://doi.org/10.3390/healthcare12141413
- Мазуров В.И., Лила А.М., Тогизбаев Г.А., Мирахмедова Х.Т., Койлубаева Г.М., Алексеева Л.И. с соавт. Евразийские рекомендации по диагностике и лечению первичного остеоартрита (2025). Ассоциация ревматологов Евразии (League of Eurasian Rheumatologists, LEAR). Современная ревматология. 2025;19(4):96–110. [Mazurov VI, Lila AM, Togizbaev GA, Mirakhmedova HT, Koilubaeva GM, Alexeeva LI, et al. Eurasian recommendations for the diagnosis and treatment of primary osteoarthritis (2025). League of Eurasian Rheumatologists (LEAR). Sovremennaya revmatologiya = Modern Rheumatology Journal. 2025;19(4):96–110 (In Russ.)].
EDN: VWBECI. https://doi.org/10.14412/1996-7012-2025-4-96-110



